INTRODUCTION
Schnitzler syndrome (SS) is a rare autoinflammatory disease with unclear etiopathogenesis. The disease is associated with cytokine dysregulation involving interleukin (IL)-1b and the inflammasome pathway and manifests with major clinical criteria, namely IgM paraprotein and urticarial rash, and minor criteria, including fever, lymphadenopathy, musculoskeletal pain, and thrombosis. 1 Anakinra is a recombinant version of human IL-1 receptor (IL-1R) antagonist and binds to IL-1R, inhibiting IL-1a and IL-1b signaling. SS typically responds dramatically to IL-1R blockade. 2 No recurrent genetic alterations have been identified in SS to date. Interestingly, a case series examining 21 SS patients sequenced 32 autoinflammatory genes without identifying a single genetic alteration in the cohorts. 3 SS carries a 15% to 20% risk of an associated lymphoproliferative disorder, similar to that of other conditions with IgM paraproteinemia, including lymphoplasmacytic lymphoma (LPL)/Waldenstr€ om macroglobulinemia (WM), and systemic amyloidosis. The precise relationship amongst hematologic disorders is unknown.
WM is an IgM-secreting LPL with clinical features including cytopenias and lymphadenopathy and paraprotein-related manifestations. MYD88 is a gene involved in nuclear factor k light chain enhancer of activated B cells (NF-kB) signaling. Mutations in MYD88 (eg, L265P) are the molecular hallmark of WM and have been identified in more than 90% of WM cases. 4 This mutation was not included in previous molecular panels investigating SS. 3 Here we present the first case, to our knowledge, of SS with MYD88 L265P mutation and explore the proposed role of this alteration in the pathogenesis of SS. Consent was obtained in accordance with University of California San Diego Institutional Review Board guidelines.
CASE
A 79-year-old man presented with a history of right inguinal lymphadenopathy for 7 years. Initial (Table I) .
Over the next 7 years, he suffered from arthralgias, bone pain, and an episodic urticarial eruption. He had a persistent leukocytosis, anemia, and elevated erythrocyte sedimentation rate (ESR). A lymph node biopsy was performed, which found monotypic CD5 -/CD10 -B cells again without malignancy (Table I) . Positron emission tomographyecomputed tomography found mild fluorodeoxyglucose-avid bilateral axillary and inguinal lymph nodes, so he was empirically treated with rituximab monotherapy without improvement.
The patient eventually presented to our clinic with persistent fatigue, chronic anemia, arthralgias, and urticarial rash (Fig 1) . Repeat bone marrow biopsy found an IgM 1 k-restricted plasmacytosis with hypercellular marrow. No B cells were identified, which excluded LPL/WM. Cytogenetic tests found a normal male karyotype. MYD88 L265P mutation was identified on next-generation sequencing (Table I) . A skin biopsy found interstitial neutrophilic infiltrates compatible with neutrophilic urticarial Performed by Pathline emerge using clone NAT105 for PD-1 staining and clone SP142 for PD-L1 staining. dermatosis related to SS (Fig 2) . Anakinra, 100-mg subcutaneous daily injections, were started, which within days led to near-complete resolution of rash and arthralgias, and hemoglobin plus ancillary inflammatory markers (thrombocytosis, ESR, and Creactive protein) normalized (Fig 3) . He remains symptom free in clinical remission on anakinra, 100 mg/d, 1 year into treatment.
DISCUSSION
We show a common alteration in LPL/WM that also represents a novel finding in SS. MYD88 plays an important role in IL-1 signaling, mediating the association between the IL-1R and its IL-1 receptoreassociated kinase (IRAK). MYD88 L265P gain-of-function mutation promotes cell survival by forming a protein complex of IRAK1 and IRAK4, contributing to increased expression of pro-inflammatory pathways. 5 Given the apparent specificity of the L265P mutation for LPL and role in promoting survival, SS and LPL appear connected and likely represent a disease continuum. Although not previously reported, this mutation may exist in a subset of SS patients who may be at the highest risk of lymphoproliferative disorder development. Therapeutically, Bruton tyrosine kinase inhibitor ibrutinib has shown significant activity in MYD88-mutated LPL; this agent also deserves evaluation in SS. 6 Further study of the genomics of SS is required with assessment of the prevalence of L265P mutation in a larger cohort. 
